BIOS Capital Management LP bought a new stake in Actuate Therapeutics (NASDAQ:ACTU - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 9,893,651 shares of the company's stock, valued at approximately $78,753,000. Actuate Therapeutics accounts for approximately 83.7% of BIOS Capital Management LP's investment portfolio, making the stock its largest holding. BIOS Capital Management LP owned approximately 50.66% of Actuate Therapeutics at the end of the most recent reporting period.
Separately, Sigma Planning Corp acquired a new stake in Actuate Therapeutics in the fourth quarter valued at $128,000.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on the company. HC Wainwright assumed coverage on Actuate Therapeutics in a research report on Monday, March 17th. They issued a "buy" rating and a $20.00 price objective on the stock. Craig Hallum assumed coverage on Actuate Therapeutics in a research report on Tuesday, April 22nd. They set a "buy" rating and a $21.00 target price on the stock.
Check Out Our Latest Analysis on Actuate Therapeutics
Actuate Therapeutics Trading Down 2.7%
NASDAQ ACTU opened at $10.26 on Tuesday. The business's 50-day moving average price is $8.28 and its 200 day moving average price is $8.29. Actuate Therapeutics has a twelve month low of $5.51 and a twelve month high of $11.73.
Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.06).
Actuate Therapeutics Company Profile
(
Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
